ストックスクリーナーアプリを入手
11.43
0.70%
0.08
アフターアワーズ：
11.43
前日終値:
$11.35
開ける：
$11.23
24時間の取引高:
504.34K
Relative Volume:
0.79
時価総額：
$796.44M
収益：
$62.71M
当期純損益:
$-112.51M
株価収益率:
-7.5695
EPS:
-1.51
ネットキャッシュフロー:
$-96.01M
1週間 パフォーマンス:
-0.95%
1か月 パフォーマンス:
-9.93%
6か月 パフォーマンス:
-18.88%
1年 パフォーマンス:
+35.59%
1日の値動き範囲:
$11.02
$11.72
1週間の範囲:
$11.02
$11.81
52週間の値動き範囲:
$8.21
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
名前
Zymeworks Inc.
セクター
電話
604-678-1388
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
11.43 | 804.15M | 62.71M | -112.51M | -96.01M | -1.51 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-07 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 再開されました | Wells Fargo | Overweight |
| 2023-01-04 | 繰り返されました | H.C. Wainwright | Neutral |
| 2022-12-20 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
| 2022-05-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-03-15 | 開始されました | Evercore ISI | Outperform |
| 2021-12-10 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Neutral |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-02-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 再開されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-08-06 | 開始されました | SVB Leerink | Outperform |
| 2020-01-10 | 開始されました | Wolfe Research | Outperform |
| 2019-12-09 | 開始されました | JP Morgan | Neutral |
| 2019-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-30 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 開始されました | Stifel | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-05-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 開始されました | Raymond James | Outperform |
すべてを表示
Zymeworks Inc. (ZYME) 最新ニュース
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Zymeworks gets China nod for Bone-partnered cancer drug - Seeking Alpha
Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks
Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus
Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - Yahoo
Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault
What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World
Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks
Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.
TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq
Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World
TD Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks (ZYME) Initiated as a Buy by TD Cowen Due to Strong Pi - GuruFocus
Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities - Seeking Alpha
Zymeworks (ZYME) Receives New Buy Rating from TD Securities | ZYME Stock News - GuruFocus
TD Cowen Initiates Coverage on Zymeworks With Buy Rating - marketscreener.com
Zymeworks (ZYME) Gains Favor with Buy Rating from TD Cowen | ZYM - GuruFocus
Zymeworks Presents Preclinical Data on ZW1528 at the American Th - GuruFocus
Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW152 - GuruFocus
Zymeworks Shows Positive Preclinical Data for Experimental Respiratory Imflammation Treatment - marketscreener.com
Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment - TipRanks
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - The Manila Times
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference | ZYME Stock News - GuruFocus
The Manufacturers Life Insurance Company Sells 1,089 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts
Analyst Forecasts For Zymeworks Inc. (NASDAQ:ZYME) Are Surging Higher - Yahoo Finance
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - simplywall.st
Zymeworks Reports Q1 2025 Financial Results and R&D Progress - TipRanks
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue S - GuruFocus
Dimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... - Yahoo Finance
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - The Manila Times
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth - GuruFocus
Zymeworks (ZYME) Surpasses Revenue Expectations in Q1 | ZYME Sto - GuruFocus
Zymeworks Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zymeworks Inc. (ZYME) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):